The Cue Biopharma platform was developed out of the laboratory of Steven Almo, Ph.D., Chair of the Department of Biochemistry at Albert Einstein College of Medicine/Montefiore Medical Center. Dr. Almo, with co-founders Ron Seidel III, Ph.D., Executive Vice President, Head of Research and Development and Rudy Chaparro, Senior Advisor, pioneered the work that led to Cue Biopharma’s Immuno-STAT platform as part of a five-year, Specialized Center grant from the National Institutes of Health (NIH). This funding enabled the technology to be built into an industry-scale drug design platform capable of rapid and efficient molecular prototyping and development. Cue Biopharma is leveraging these design capabilities in its discovery efforts.

Founders-Ron-Seidel

Ronald D. Seidel III, Ph.D.

Executive Vice President, Head of Research and Development
Founders-Steven-Almo

Steven Almo, Ph.D.

Co-Founder and Chair of SAB
Founders-Rudy-Chaparro

Rodolfo J. Chaparro, Ph.D.

Co-Founder